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Abstract
Background: Lymphangiomas are neoplasias of childhood. Their etiology is unknown and a causal
therapy does not exist. The recent discovery of highly specific markers for lymphatic endothelial
cells (LECs) has permitted their isolation and characterization, but expression levels and stability
of molecular markers on LECs from healthy and lymphangioma tissues have not been studied yet.
We addressed this problem by profiling LECs from normal dermis and two children suffering from
lymphangioma, and also compared them with blood endothelial cells (BECs) from umbilical vein,
aorta and myometrial microvessels.
Methods: Lymphangioma tissue samples were obtained from two young patients suffering from
lymphangioma in the axillary and upper arm region. Initially isolated with anti-CD31 (PECAM-1)
antibodies, the cells were separated by FACS sorting and magnetic beads using anti-podoplanin and/
or LYVE-1 antibodies. Characterization was performed by FACS analysis, immunofluorescence
staining, ELISA and micro-array gene analysis.
Results:  LECs from foreskin and lymphangioma had an almost identical pattern of
lymphendothelial markers such as podoplanin, Prox1, reelin, cMaf and integrin-α1 and -α9.
However, LYVE-1 was down-regulated and VEGFR-2 and R-3 were up-regulated in lymphangiomas.
Prox1 was constantly expressed in LECs but not in any of the BECs.
Conclusion: LECs from different sources express slightly variable molecular markers, but can
always be distinguished from BECs by their Prox1 expression. High levels of VEGFR-3 and -2 seem
to contribute to the etiology of lymphangiomas.
Background
The blood vascular system supplies all organs with oxygen
and nutrients while the lymphatic vasculature is crucial
for the uptake of extra-cellular fluid, lipids from the gut
and circulating immune cells during immune surveil-
lance. Unfortunately, the lymphatics also serve as high-
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ways for metastatic tumour cells. Both vascular systems
are anatomically and histologically closely related to each
other, but they are also different as concerns their topog-
raphy, architecture of their walls, and their cellular and
molecular composition (reviews see [1-4]). In spite of the
importance of lymphatic vessels in health and disease, e.g.
80% of carcinomas metastasize via the lymphatic system,
they have received little attention until recently. This has
been due to the absence of suitable markers that distin-
guish between lymphatic endothelial cells (LECs) and
blood vascular endothelial cells (BECs). Recently, LEC
markers have been discovered and characterized, includ-
ing the hyaluronan receptor LYVE-1, the membrane glyc-
oprotein podoplanin, the transcription factor Prox1 and
the VEGFR-3 tyrosine kinase [5-8]. Use of these markers
and the generation of new antibodies have permitted the
isolation and characterization of relatively pure popula-
tions of BECs and LECs. The different isolation procedures
described in the literature include fluorescence-activated
cell sorting (FACS) and magnetic separation (MACS).
Besides pan-endothelial molecules like CD31 (PECAM-
1), the BEC marker CD34 together with LEC specific anti-
podoplanin antibodies have been used for the separation
of BECs and LEC from dermal cell suspension [9]. Some
groups have successfully used micro-beads with antibod-
ies against VEGFR-3, podoplanin or LYVE-1 [10-15].
However, the previous studies have used antibodies,
which were not commercially available, and the primary
LECs were derived from only one source, the foreskin of
healthy neonates. Commercially available primary
human dermal microvascular endothelial cells
(HDMECs) are a mixture of BECs and LECs. Heterogene-
ity of microvascular ECs from other commercial sources
(UtMVECmyo) has not been tested. Importantly, the
molecular profile of LECs from diseased tissues, such as
lymphangiomas, has not been characterized yet, which is
an important diagnostic step toward treatment of the dis-
ease.
In the present study we investigated if LECs from different
sources possess stable markers, and if primary cells from
lymphangiomas overexpress molecules involved in the
VEGF signalling pathway. Therefore, we compared a vari-
ety of blood and lymph endothelial markers by using
commercially available antibodies, commercially availa-
ble primary cells and LECs from two lymphangioma
patients. Cells from lymphangiomas were isolated by a
combination of "cell sweeping" and paramagnetic micro-
bead selection. For the separation of commercially availa-
ble primary cells, FACS and MACS sorting were used, and
characterization of the cells was performed at RNA and
protein levels. Our studies show that some LEC markers
are variable whereas others, such as Prox1, can be used to
distinguish reliably between LECs and BECs. Further-
more, our studies suggest that high levels of VEGFR-3 and
-2 may contribute to lymphangioma formation.
Methods
Cell lines, tissue samples and cell culture
Primary human dermal microvascular endothelial cells
(HDMEC) were purchased from Clonetics (neonatal
pooled, Cambrex, Inc.) and from PromoCell (Promocell
GmbH). Primary human umbilical vein endothelial cells
(HUVECs) were from PromoCell, and primary human
aorta endothelial cells (HAEC) and human myometrial
uterine microvascular endothelial cells (UtMVEC-Myo)
were from Clonetics/Cambrex. They were cultured in
endothelial growth medium, EGM-2MV (PromoCell) or
ECGM-MV2 (Clonetics).
LECs from lymphangiomas were isolated from two male
patients, 10 and 4 months of age. Lymphangiomas were
located in the axillary region of patient A, and in the upper
arm of patient B. The studies were approved by the hospi-
tal's ethics committee and were performed by the
informed consent of the patient's parents. Explants of
endothelial cells were cultured over 4–6 weeks and, using
the "cell sweeping" procedure two times per week, con-
taminating stromal cells were removed. This procedure
has been described in detail before [16]. Explants, which
did not appear to be pure after this procedure, were sorted
with micro-beads coated with CD31 antibodies (see
below) to remove contaminating fibroblasts.
LECs or mixed populations of LECs and BECs were cul-
tured in the presence of 200 – 300 ng/ml dNdC-VEGF-C.
All cells were grown on gelatinized plates and split 1:2 or
1:4 when they were confluent, and were used not longer
than passage 7–8. Recombinant dNdC- VEGF-C was
expressed and purified as described [17].
Antibodies
We used mono- and polyclonal antibodies against human
proteins. The mouse mAbs anti-CD31/PECAM-1 (WM59)
and anti-CD34 (563) were purchased from BD/Pharmin-
gen. Rabbit pAb anti-von Willebrand Factor was pur-
chased from DAKO. The mouse mABs anti-Tie2 (clone
16) and anti-KDR/VEGFR-2 (3G2) were gifts from Dr. B.
Barleon, Reliatech GmbH, as were the rabbit pABs anti-
LYVE-1, anti-CD105/endoglin and anti-Prox1. Goat anti-
mouse, goat anti-rabbit and CD31 micro-beads were pur-
chased from Miltenyi Biotec. Mouse mAbs anti-VEGFR-3
(2E11 and 9D9F9 [18] and Tie1 (9F12) were gifts from
Dr. K. Alitalo (University of Helsinki, Finland). Mouse
mAbs anti-podoplanin and rabbit pAbs anti-podoplanin
were gifts from Dr. D. Kerjaschki (Medical University,
Vienna, Austria). Also mouse mAb anti-podoplanin/gp36
(18H5) was a gift from Dr. G. Zimmer (University of Vet-
erinary Medicine, Hannover, Germany).BMC Cancer 2007, 7:105 http://www.biomedcentral.com/1471-2407/7/105
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FACS analysis and cell sorting
Confluent monolayers of ECs were dissociated by incuba-
tion with accutase (PAA). Cell pellets were re-suspended
in PBS containing 2% FCS to a final number of 5 × 104
cells/sample, and incubated for 30 min on ice with 1 μg/
ml anti-CD31, 2 μg/ml CD34, 5 μg/ml anti-podoplanin
(G.Z.), 1:500 diluted anti-podoplanin (D.K.), 5 μg/ml
anti-Tie1, 2 μg/ml anti-Tie2, 5 μg/ml anti-VEGFR-1/Flt-1,
5 μg/ml anti-VEGFR-2/KDR, and 4–6 μg/ml anti-VEGFR-
3/Flt-4. Rabbit antibodies were used as follows: 1:1000
dilution for anti-podoplanin (D.K.), 1 μg/ml anti-LYVE-1
and 5 μg/ml anti-CD105/endoglin. Primary antibody
binding was revealed with FITC-labelled goat-anti-mouse
or anti-rabbit antibodies (Dianova GmbH). Negative con-
trols were performed by omission of the first antibody.
Dead cells were stained with propidium iodide. Cells were
analysed by flow cytometry using FACS-Calibur and Cel-
lQuest software (BD). Overlays were executed with either
CellQuest or Winmdi software (Joe Trotter, The Scripps
Research Institute).
FACS sorting was done with a FACS-Vantage SE instru-
ment using 0.5 -1 × 106 cells and the mouse-anti-podo-
planin (G.Z.) and rabbit-anti-Lyve-1 antibodies. Besides
goat-anti-rabbit FITC-conjugated also goat-anti-mouse
PE-conjugated antibodies or rat-anti-biotin PE-conju-
gated antibodies were used for the isolation of double
positive cells.
Magnetic cell sorting
Magnetic labelling and separation was used for the isola-
tion of LECs from lymphangiomas by positive sorting
with CD31 paramagnetic micro-beads, if the cultures were
contaminated with fibroblasts. For the isolation of LECs
from human dermal microvascular endothelial cells, the
antibodies mouse-anti-podoplanin (G.Z.) and rabbit-
anti-Lyve-1 were used. For each separation, 0.2 – 1.5 × 106
cells were used and disaggregated by accutase as described
for FACS analysis. For the separation process a MidiMACS
separator with LS columns was used as recommended by
the supplier (Miltenyi Biotec). A detailed isolation proce-
dure for this method has been reported before [19]. After
separation with micro-beads, cells were further cultured
(> 8.000 cells/cm2 in the presence of VEGF-C) for immu-
nostaining and for FACS analysis.
Immunofluorescence
For immunofluorescence-staining cells were directly
seeded in 100 mm cell culture dishes or seeded in Lab-Tek
II chamber slides (Nunc) coated with poly-lysine (5 μg/
cm2 in PBS) or with gelatine. Confluent cells were fixed 5
min with 4% paraformaldehyde. ECs were incubated for
15–30 min at room temperature in blocking buffer (1%
bovine serum albumin in PBS) and permeabilization was
achieved by incubation with 0.1% Triton X-100 for one
minute. Cells were incubated 60 min with primary anti-
bodies and 45 min with the secondary antibodies (FITC-
or TRITC-labelled). Nuclei were counter-stained with 0.5
mg/ml 4',6-Diamidino-2-phenylindole (DAPI; Sigma).
VEGFR-3 ELISA
The quantification of VEGFR-3 in cell lysates by ELISA has
been described in detail before [20]. Briefly, confluent
cells were homogenized in RIPA buffer (0.1% SDS, 1%
Triton X100, 0.5% Na-deoxycholate, protease inhibitor
cocktail in PBS) and protein concentrations were esti-
mated according to a standard protocol (BCA assay, Per-
bio). Test samples were diluted at least 1:2 or 1:4 in
dilution buffer. If necessary, higher dilutions were made.
Each dilution was measured in triplicate.
Micro-array analysis
Micro-arrays were performed at the micro-array core facil-
ity of the Medical Faculty of the Georg-August-University,
Goettingen, Germany. We compared the expression pro-
files of LECs from each lymphangioma patient with that
of HUVECs. Fluorescent dye-labelled probes for hybridi-
zation were produced with SMART fluorescence probe
amplification kit (BD Biosciences). During reverse tran-
scription of RNA, the resulting single stranded cDNA was
elongated by introducing specific adaptor sequences at
both the 5' and 3' ends. In an amplification step, a double-
stranded cDNA was synthesized by PCR amplification to
produce the amounts of probe necessary for hybridization
(Eppendorf), using primers corresponding to the adaptor
sequences. Following cDNA synthesis, aminoallyl-modi-
fied dUTP was incorporated into the cDNA during several
rounds of primer extension. In a coupling step, N-hydrox-
ysuccinimide-activated Cy3 and Cy5 dyes (Amersham
Bioscience) reacted specifically with the modified dUTPs
in the cDNA, producing labelled probes. The dye absorb-
ance was measured with NanoDrop ND-1000 spectro-
photometer to calculate the dye incorporation ratio per μg
DNA. For hybridization of the probes, a mixture of Cy5
and Cy3 labelled probes was prepared. Per Array (44 k
whole genome oligo micro-arrays; Agilent) 0.7 – 1.5 μg of
Cy-labelled DNA was used. Hybridization was performed
according to the Agilent '60-mer oligo micro-array
processing protocol. Fluorescence intensities were meas-
ured with Agilent micro-array scanner. Normalization of
the raw micro-array data was performed with non-linear
loss regression. Differentially expressed genes were identi-
fied by ANOVA-procedure. The resulting p-values from
the test statistics for significance were adjusted with the
Benjamini-Hochberg method to control the False-Discov-
ery-Rate.BMC Cancer 2007, 7:105 http://www.biomedcentral.com/1471-2407/7/105
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Results
HUVECs and HAECs are negative for lymphatic 
endothelial markers
As a negative control for our studies on LEC markers we
have used two types of large vessel endothelial cells iso-
lated from human umbilical vein (HUVEC) and aorta
(HAEC). These cell types are from distinct blood vessels,
either from venous or arterial localization, and are well
characterized and commercially available. For FACS anal-
ysis we used the pan-endothelial markers CD31/PECAM-
1, Tie-2 receptor and CD105/endoglin. Both vascular cell
types were positive for the selected surface markers and
there were only minor differences in the expression levels
between the two cell types (Fig. 1). Antibodies against
podoplanin have been used in several studies to isolate
LECs [10,9], since podoplanin is a good marker for LECs
and lymph vessels [21]. Besides podoplanin, LYVE-1 is a
well-established marker for lymphatic vessels [5]. Only a
minor subpopulation of HAECs expressed LYVE-1 at a low
level (Fig. 1). Cell sorting with this polyclonal antibody is
possible, but compared to podoplanin we often received
a broader peak over a wider range, indicating a variable
number of epitopes on the cell surface. However, only a
small subpopulation of arterial and venous BECs were
positive for LYVE-1. Von Willebrand factor is one of the
best-characterized markers for endothelial cells. All cells
from both types of large blood vessels were positive for
this marker (Fig. 2). Also PECAM-1 stains all cell mem-
branes from endothelial cells. The transcription factor
Prox1 is one of the most stringent markers for LECs in vitro
and for lymphatic vessels in tissue sections, and has been
used for immunostaining since several years [7,22]. As
expected, HUVECs and HAECs were negative for Prox1,
showing that these are pure population of BECs (Fig. 2).
Human dermal microvascular endothelial cells as a source 
for BECs and LECs
Commercially available microvascular endothelial cells
from foreskin of human neonates (HDMECs) have been
used in recent years as a source for the isolation of LECs.
These cultures contain a mixed population of BECs and
LECs, and several protocols have been reported for the
separation and culture of both types of vascular cells [19].
We have also used HDMECs from two different compa-
nies and tested two different separation methods with dif-
ferent antibodies in order to isolate LECs. First, we used
micro-bead separation with podoplanin antibodies as
reported recently [19]. This isolation method resulted in
approximately 60–80% positive cells. Micro-bead separa-
tion with LYVE-1 antibodies is also possible, but results in
only 15–40% of LYVE-1-positive cells. Similar results were
found when FACS sorting was used. Here we applied the
antibodies against podoplanin and LYVE-1 in combina-
tion (Fig. 3). A high percentage of the cells were positive
for podoplanin and a substantial part of the population
was podoplanin+/LYVE-1+ (Fig. 3). An unexpected high
percentage of LECs was found in a recent study when the
same primary cells were used for characterization [23].
Expression of blood and lymphatic markers on large vessel endothelial cells Figure 1
Expression of blood and lymphatic markers on large vessel endothelial cells. Typical profiles obtained by FACS anal-
ysis with the panendothelial markers CD31/PECAM-1, Tie2 and CD105/endoglin on primary HUVECs and HAECs (passage 3–
5). Profiles obtained with lymphatic markers podoplanin and LYVE-1 on both of the control cell types are also indicated. The 
mean fluorescence intensities were normalized to the background fluorescence of the secondary antibody alone (grey).BMC Cancer 2007, 7:105 http://www.biomedcentral.com/1471-2407/7/105
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The podoplanin+, LYVE-1+, and podoplanin+/LYVE-1+
cells were further cultured and analysed for LEC markers.
A typical profile is shown in Fig. 4 + 5. As expected, podo-
planin+ cells showed an increase in the two LEC markers
LYVE-1 and VEGFR-3. However, this increase was moder-
ate and not all podoplanin+ cells were also positive for
LYVE-1 and VEGFR-3 (Fig. 5). Subcultures of podo-
planin+, LYVE-1+ or double-positive cells studied by FACS
analysis revealed a certain percentage of cells negative for
the surface markers, which were initially used for sorting.
This may indicate that these cells down-regulate the
expression levels of LYVE-1 and VEGFR-3.
We next assessed the expression of the transcription factor
Prox1, as one of the most reliable markers for LECs [1,12].
Immunofluorescence was used to analyse Prox1 expres-
sion at the protein level. Most of the primary cells from
foreskin (passage 4–7) were already positive for this
marker, and after LYVE-1 or podoplanin selection almost
100% of the cells were positive for Prox1 and CD31 (Fig.
6). These cells could also be stained with LYVE-1 and
podoplanin antibodies (Fig. 6).
Myometrial microvascular endothelial cells are positive for 
LYVE-1, but negative for podoplanin and Prox1
Normal human uterine microvascular endothelial cells
isolated from the myometrium (UtMVECmyo) are com-
mercially available. We followed the question are these
cells also a mixture of BECs and LECs. Results obtained
with this cell type were surprising. Cultured cells were pos-
itive for LYVE-1, but negative for podoplanin (Fig. 7). Fur-
thermore, immuno-fluorescence was used to analyze
Prox1 expression in vitro. Prox1 was undetectable, like
podoplanin, whereas more than 90% of the cells were
positive for LYVE-1 as estimated by DAPI counter-stain-
ing.
Lymphatic endothelial cells isolated from lymphangiomas
In the current study we had the unique possibility to iso-
late and characterize LECs from lymphangiomas of two
Expression of von Willebrand factor (vWF), CD31/PECAM-1 and Prox1 in large vessel control cells Figure 2
Expression of von Willebrand factor (vWF), CD31/PECAM-1 and Prox1 in large vessel control cells. Granular 
intracellular localization of vWF, membranous localization of CD31 and nuclear localization of Prox1 was detected by immuno-
cytology in HUVEC and HAEC. Nuclei were counter-stained with DAPI. One representative staining out of several independ-
ent experiments is shown. Magnification, × 200.BMC Cancer 2007, 7:105 http://www.biomedcentral.com/1471-2407/7/105
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young children. Both patients suffered from lymphangi-
oma in the axillary and upper arm region. Both methods,
"cell sweeping" and CD31 micro-bead sorting of mixed
cell populations have lead to pure populations of LECs,
about 4 – 6 weeks after surgical removal of the lymphvas-
cular malformation. The cells from patient A had a cob-
blestone characteristic and microscopic morphology very
similar to other primary endothelial cells (Fig. 8). Cells
from patient B looked very similar (Fig. 9). The cells were
cultured with the same medium as for microvascular ECs,
but VEGF-C was added to the medium. This mitogen is
specific for LECs [19] and helps to maintain cell viability
and cell type characteristics under culture conditions.
Expression of lymphatic markers was further analyzed by
immunological methods. All isolated cells from patient A
were CD31+ and Prox1+. Furthermore, these cells could
also be stained with podoplanin antibodies. They showed
a very homogenous expression for podoplanin (Fig. 8d).
Cells from patient B were generated similarly by "cell
sweeping " and sorting with CD31 microbeads (Fig. 9).
Staining with Prox1 confirmed that all cells possessed LEC
characteristics (Fig. 9d). We next assessed the expression
of a variety of EC markers by FACS analysis. We found that
besides PECAM1 they were positive for Tie1, Tie2 and
VEGFR-2 (Fig. 10).
We also tested three different antibodies against podo-
planin. All of them gave a positive result. However, in
contrast to the dermal LECs, LECs from lymphangiomas
were either negative for LYVE-1 or expressed this marker
only at low levels (Fig. 11). These results could be con-
firmed by immunofluorescence (not shown). Both of the
LEC populations were positive for VEGFR-3, but expres-
sion appeared to be relatively low. However, the results
obtained with the VEGFR-3 antibodies in the FACS analy-
ses were variable. We therefore quantified VEGFR-3
expression with a recently developed sandwich ELISA that
uses different VEGFR-3 antibodies [20]. The amount of
VEGFR-3 protein in the lysates from large blood vessel
endothelial cells was very low (1.4 – 2.7 ng/mg). UtM-
VECmyo were almost negative for VEGFR-3 protein (1.6
ng/mg), indicating that they are BECs rather than LECs,
with the peculiarity, that they are positive for LYVE-1. In
the lysates prepared from LECs originating from LYVE-1
sorting of HDMECs, VEGFR-3 protein concentrations
increased to 19.3 ng/mg, while LECs from lymphangi-
omas reached values of 29.5 – 40.8 ng/mg, which was sig-
nificantly higher than the concentrations found in
foreskin LECs (Table 1).
For a broader characterization of the LECs from the two
lymphangioma patients, we studied their gene expression
profile in comparison to HUVECs (Table 2). The studies
confirm the lymphendothelial origin of the cell, since we
found expression of a large number of molecules that
have previously been found by others in dermal LECs [12-
14]. This applies to markers such as Prox1, podoplanin,
reelin, c-Maf, macrophage mannose receptor and TIMP 3,
as well as to growth factors and receptors such as FGF-12,
TGF-α, neuropilin-2, integrin-α 9 and integrin-α1. Addi-
tionally, we found a large number of highly expressed LEC
genes in the whole genome micro-arrays, which have not
been detected previously, due to limitations of the micro-
arrays used (data not shown). However, the levels for
Lyve-1 and VEGFR-3 were not as high as could have been
expected. The RNA data for Lyve-1 were in agreement with
the variable results of the FACS analyses, however, the
RNA data for VEGFR-3 were lower than could have been
expected from the ELISA data, indicating high stability of
the protein. In patient-B, we found very high levels of
VEGFR-2 in the lymphangioma LECs, and both expres-
sion of VEGFR-2 and VEGFR-3 could be confirmed by
immunostaining of tissue sections (data not shown).
Additionally we observed expression of the adapter pro-
tein shc, phospholipase-Cγ (PLCγ) and p44 MAP kinase,
which are involved in VEGFR-2 and -3 signal-transduction
(review: 2). The data suggest that signalling via VEGFR-2
and -3 may be involved in lymphangioma formation.
Characterization of LECs isolated from dermal microvascular  endothelial cells Figure 3
Characterization of LECs isolated from dermal 
microvascular endothelial cells. FACS sorting of 
HDMECs with the two antibodies against podoplanin and 
LYVE-1. Only podoplanin+ cells are found in gate R3 and 
podoplanin+/LYVE-1+ cells are found in gate R4. A total 
number of 9,6 × 105 cells from passage 6 have been used for 
cell sorting.BMC Cancer 2007, 7:105 http://www.biomedcentral.com/1471-2407/7/105
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Discussion
The main functions of the lymphatic vascular system are
to maintain the fluid balance in the interstitial spaces, to
provide a highway for circulating leukocytes, and to take
up and transport larger particles such as chylomicrons and
bacteria. These important functions of lymphatic vessels
in health and disease are well known, but have rarely been
studied experimentally (review: [4]). Malformations of
lymphatic vessels, such as lymphangiomas, are associated
with a failure in lymph transport and high morbidity of
the patients [24]. The etiology of lymphangiomas is
unknown, which may not be surprising, because even the
mechanisms of normal embryonic development of lym-
phatic vessels are still a matter of debate (review: [2]).
Some authors assume that lymphatic vessels are exclu-
sively derived by sprouting from the venous system,
whereas others suggest that there is an additional origin
from mesenchymal lymphangioblasts [25]. A few "lym-
phangiogenesis" genes have been identified in patients
presenting with congenital lymphedema, due to hypopla-
sia or dysplasia of the lymphatic vascular system. Milroy
lymphedema in some, but not all, affected families is due
to mutations in the VEGFR-3 gene [26,27], which encodes
the receptor for the lymphangiogenic growth factors
VEGF-C and -D [3]. Lymphedema-distichiasis is linked to
the forkhead transrciption factor FOXC2 [28], and the
lymphedema-hypotrichosis-telangiectasia syndrome is
caused by mutations in the transcription factor SOX18
[29]. However, besides lymphangioma, there are approx-
imately 40 syndromes that are associated with abnormal
development of the lymphatic vascular system [30]. The
isolation and characterization of LECs from normal and
malformed tissues will facilitate the characterization of
the diseases, as a first step for diagnosis and therapy.
Isolation and characterization of LECs
Isolation studies have concentrated on LECs from fore-
skin and not from other tissues. Characterization of LECs
from different healthy or diseased tissues has not been
carried out. We have started to address this question and
isolated LECs from normal and diseased tissues with com-
mercially available antibodies. The expression and distri-
bution of blood and lymph vessel markers was analyzed
at RNA level with micro-arrays and at protein level by
FACS analysis, immunocytology and ELISA. The main
results of our studies show that
FACS analysis of blood markers on dermal microvascular endothelial cells before and after podoplanin magneto-bead sorting Figure 4
FACS analysis of blood markers on dermal microvascular endothelial cells before and after podoplanin mag-
neto-bead sorting. Typical profiles obtained with the panendothelial markers CD31/PECAM-1, Tie2 and CD105/endoglin on 
primary HDMECs and on the same cells (passage 3–5) after podoplanin sorting with magneto beads.
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(i) LEC markers vary among the types of tissue used for
cell culture
(ii) microvascular endothelial cells from the myometrium
are a homogenous population of BECs, but positive for
LYVE-1
(iii) LECs from lymphangiomas compared to those from
foreskin have numerous markers in common, but show
decreased LYVE-1 and increased VEGFR-3 expression
(iv) Prox1 is by now the most reliable marker of LECs.
Our data are in line with and extend previous studies
demonstrating that LECs can be isolated from neonatal
foreskin and identified by their ability to express markers
like VEGFR-3, podoplanin and LYVE-1 [5,13,14].
Human dermal microvascular endothelial (HDMECs)
have a high capacity to express lymphatic markers, and we
observed that BECs seem to make up the minority of cells
after primary isolation. This has also been observed in
studies where these cells were used for immortalization
[23]. It is not known by now, if directly after the initial iso-
lation of the cells from foreskin with anti-CD31 antibod-
ies by the supplier LECs are the numerical dominant cell
type, or if during further expansion and splitting of the
cultures the population of LECs preferentially increases.
In initial experiments with HDMECs we found that the
percentage of podoplanin+ cells is very high (60–90%).
Further characterization of the cells by FACS analyses
showed that some batches can be divided into three
groups: podoplanin-negative, moderately positive and
strongly positive. However, most of the batches contain
only two groups: podoplanin- and podoplanin+ (data not
shown). Approximately 50% of the podoplanin+ cells are
also positive for LYVE-1, and these are the same cells,
which are also positive for VEGFR-3. At the moment it
remains unclear, if podoplanin+/LYVE-1- cells represent
an intermediate cell-type, and if only the podoplanin+/
LYVE-1+/VEGFR-3+ cells can be regarded as primary LECs
from neonatal foreskin.
Growth of cultured LECs depends on the presence of
VEGF-C, which, in mixed cultures, is supplied by the BECs
[3]. After separation of LYVE-1+ or podoplanin+ cells we
cultured them in the presence of VEGF-C as recom-
mended before. However, selective stimulation of VEGFR-
2 by VEGF-E is obviously also sufficient to grow and
expand LECs in culture [31]. The activity profile of
FACS analysis of lymphatic markers on dermal microvascular endothelial cells before and after podoplanin magneto-bead sort- ing Figure 5
FACS analysis of lymphatic markers on dermal microvascular endothelial cells before and after podoplanin 
magneto-bead sorting. Typical profiles obtained with lymphatic markers podoplanin, LYVE-1 and VEGFR-3 before and after 
podoplanin-mediated cell sorting with a FACS sorter
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another family of endothelial growth factors, the angi-
opoietins (e.g. Ang-1 and Ang-2) is still controversially
discussed. Angiopoietins bind the Tie2 receptor, and may
activate or inhibit signal transduction in a cell-type and
tissue-specific manner [32,33]. Angiopoietins are essen-
tial for the hierarchical organization of the blood vascular
tree, but the expression of Tie2 in lymph vessels of the
human has remained unclear. We have observed Tie2
expression in LECs sorted with anti-podoplanin antibod-
ies from HDMECs, as well as Tie1 and Tie2 in LECs from
lymphangioma patients. Mice deficient in Ang-2 show
defects in the patterning and function of the lymphatic
vasculature, and a lack of lymph nodes, and they develop
chylous ascites [33]. Overexpression of Ang-1 in the skin
of adult mice induces lymphangiogenesis, which is asso-
ciated with VEGFR-3 up-regulation in LECs. Interestingly,
proteolytically processed VEGF-C, which binds VEGFR-2
and -3, induces Ang-2 expression in LECs in vitro via
VEGFR-2 signalling, indicating a new interaction between
the VEGF and angiopoietin family members, which may
regulate the hierarchy of the lymphvascular tree [34].
Lymphangioma endothelial cells
Lymphangiomas are disfiguring neoplasias of childhood
and may also manifest or enlarge rapidly in adulthood
[35]. More than 95% of lymphangiomas occur in the soft
tissues of the head, neck and axilla, with less than 5%
occurring in the abdominal cavity. The prevalence of lym-
phatic malformations is 1.2 – 2.8‰ [36]. Macroscopi-
cally lymphangiomas are solitary, multicystic masses. The
lining of the cysts is smooth and they have thin walls. His-
tological criteria for lymphangiomas are: 1) lymphatic
spaces lined by endothelium, 2) fascicles of smooth mus-
cle in the septa, and 3) lymphoid aggregates in the delicate
collagenous stroma [37]. Immunoelectron microscopic
studies have demonstrated up-regulation of CD31 and
CD34 and show type IV collagen expression in lym-
phangiomas [38]. The vascular endothelial marker PAL-E
is confined to blood vessels in lymphangiomas. VEGFR-3
mRNA has been localized to lymphangioma LECs [8]. The
detection of transcripts for VEGF-C, VEGFR-2 and VEGFR-
3 in endothelial cells from different lymphangiomas by in
situ hybridization was reported before [39]. No expres-
Expression of CD31/PECAM-1, LYVE-1 and Prox1 in dermal microvascular endothelial cells before and after LYVE-1 sorting Figure 6
Expression of CD31/PECAM-1, LYVE-1 and Prox1 in dermal microvascular endothelial cells before and after 
LYVE-1 sorting. Membranous localization of CD31, LYVE-1 and podoplanin, and nuclear localization of Prox1 was detected 
by immunocytology in HDMECs. Nuclei were counter-stained with DAPI in some specimens. One representative staining out 
of several independent experiments is shown. Magnification, × 200.BMC Cancer 2007, 7:105 http://www.biomedcentral.com/1471-2407/7/105
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sion of these genes was found in adjacent tissue or in nor-
mal lymphatic vessels.
With immunohistological methods, we have recently
been able to identify VEGFR-3 and Prox1 in CD31-posi-
tive LECs of lymphangiomas [22].
Here we have measured the amount of VEGFR-3 protein
in lysates from different endothelial cell types and found
significantly higher expression in LECs derived from the
two lymphangioma patients as compared to foreskin
LECs. Significant amounts of VEGFR-3 and its intra-cellu-
lar signalling cascade (shc, PLCγ, p44MAPK) were also
detectable at RNA level. Increased VEGFR-3 signalling
may be a major course for aberrant lymph vessel forma-
tion since the opposite, lymphatic hypoplasia, can be
observed in VEGFR-3 mutated patients with Milroy's dis-
ease [26,27]. The reasons or regulatory pathways for
VEGFR-3 up-regulation are not known. Direct (muta-
tions) or indirect mechanisms have to be considered, e.g.
an increase of Ang-1 expression, as discussed above. How-
ever, we did not detect Ang1 or Ang2 expression in lym-
phangioma LECs at significantly higher levels as
compared to HUVECs. Because lymphangioma tissue
mainly consists of LECs and stromal cells, the ligands for
VEGFR-3, VEGF-C and VEGF-D, may be derived from
either of the cell types, acting in an auto- or paracrine
mode, respectively. However, we have not found any
measurable VEGF-C protein in the conditioned media
obtained from stromal cells of the two patients. Also, we
did not observe significant levels of VEGF-C and -D in the
LECs. Other growth factors may be involved in the devel-
opment of lymphangiomas. We have observed high
expression of FGF-12 and TGF-α in lymphangioma LECs,
but the significance of this finding remains to be studied.
In contrast to BECs, LECs seem to be highly responsive to
stimulation with hepatocyte growth factor (HGF) [15],
but we could not detect significant expression of the HGF
receptor, c-Met, in lymphangioma LECs as compared to
HUVECs. We have found high levels of VEGFR-2 in the
LECs from the lymphangioma patients as compared to
HUVECs (Table 2). This is a surprising finding because
usually VEGFR-2 mRNA levels of BECs and LECs are
equal, or they are lower in LECs [12,13]. We did not find
significant mRNA levels of the ligands PlGF, and VEGF-B
in the LECs and only in patient-A there was high expres-
sion of VEGF-A, which may indicate an autocrine loop.
Further studies with the cells in vitro and in situ will be nec-
Expression of lymphatic markers on UtMVECmyo Figure 7
Expression of lymphatic markers on UtMVECmyo. A: Typical FACS analysis profiles obtained with the panendothelial 
marker CD31/PECAM-1 and the lymphendothelial markers LYVE-1 and podoplanin. B: Immunostaining for CD31, Prox1, 
podoplanin and LYVE-1. Nuclei were counter-stained with DAPI. One representative staining out of several independent 
experiments is shown. Magnification, × 200.
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essary to identify the underlying mechanisms involved in
LEC hyperplasia and dysplasia.
Conclusion
We have developed methods to isolate LECs from normal
dermis and lymphangioma tissues. The transcription fac-
tor Prox1 is a stable marker of LECs, whereas surface
markers are regulated and variable. Characterization of
lymphangioma LECs suggests an involvement of VEGFR-
3 and -2 in the etiology of the disease. Gene array analyses
have revealed large numbers of molecules involved in the
regulation of growth, differentiation and function of
LECs, and call for further functional characterization.
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Isolation and characterization of LECs from lymphangiomas Figure 8
Isolation and characterization of LECs from lymphangiomas. Lymphendothelial cells (LECs) from lymphangioma 
explants isolated by „cell sweeping” were photographed under phase contrast microscopy. a) The cells from patient-A show 
the typical cobblestone morphology and are contact inhibited (passage 7, magnification, × 40.). Expression of CD31/PECAM-1 
together with Prox1 in LECs (b). Membranous localization of CD31 and nuclear localization of Prox1 was detected by immu-
nocytology. Magnification, × 200. c) Same specimen as in b) showing CD31 expression and nuclear counter-staining with DAPI. 
Magnification, × 200. d) Podoplanin staining. Nuclei were counter-stained with DAPI. One representative staining out of sev-
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FACS analysis of blood vessel markers on LECs from lymphangioma patients Figure 10
FACS analysis of blood vessel markers on LECs from lymphangioma patients. Expression of blood endothelial 
markers. Typical profiles obtained with the panendothelial markers CD31/PECAM-1, Tie1, Tie2 and VEGFR-2 on primary LECs 
from the two patients A and B (passage 4–6). All of the markers are expressed.BMC Cancer 2007, 7:105 http://www.biomedcentral.com/1471-2407/7/105
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FACS analysis of lymph vessel markers on LECs from lymphangioma patients Figure 11
FACS analysis of lymph vessel markers on LECs from lymphangioma patients. Expression of lymph endothelial 
markers on LECs from lymphangioma patients. Typical profiles obtained with the markers podoplanin (three different antibod-
ies for LEC-B), LYVE-1 and VEGFR-3 on primary LECs from the two patients A and B (passage 4–6).BMC Cancer 2007, 7:105 http://www.biomedcentral.com/1471-2407/7/105
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Table 2: Expression profile of lymphangioma LECs compared to HUVECs using Agilent gene micro-arrays
Molecule Patient A P-Value Patient B P-Value
LEC markers
Prox1 5.21 3.2779e-05 5.34 3.0458e-05
5.00 0.000114 5.47 8.7549e-05
Podoplanin 7.26 0.000538 6.23 0.000847
Reelin 5.64 0.000634 5.12 0.000844
c-Maf 4.45 0.000177 5.17 0.000113
Macrophage mannose receptor 3.96 0.000157 4.48 0.000109
TIMP 3 5.60 2.3392e-05 5.80 2.1012e-05
Lyve-1 2.75 0.001547 1.89 0.004617
VEGFR-3 1.73 0.009537 2.38 0.003869
2.54 0.000704 3.30 0.000323
Growth factors and receptors
VEGFR-2 1.91 0.005006 4.18 0.000506
1.33 0.085223 4.08 0.004490
Neuropilin-2 1.59 0.000646 2.89 0.000107
1.47 0.001513 3.34 0.000133
1.19 0.009847 3.09 0.000614
FGF-12 1.56 0.001699 2.67 0,000344
0.98 0.005359 2.59 0,000304
TGF-α 5.03 0.000273 5.32 0.000230
Integrin-α9 2.46 0.000592 2.35 0.000677
1.15 0.002815 1.70 0.000912
Integrin-α1 4.22 0.003322 2.69 0.011953
VEGFR-2 and -3 signalling
SHC 2.34 0.000219 3.20 8.6303e-05
1.73 0.000303 2.50 0.000100
PLCγ-1 1.80 0.000291 0.69 0.004961
PLCγ-2 n.r. - 1.27 0.005680
MAPK3/ERK1 0.40 0.029350 1.63 0.000559
MAPK1/ERK2 -0.84 0.005289 -0.62 0.012707
-0.45 7.9235e-06 -0.21 8.2757e-05
NF-kappaB1 0.27 0.026460 0.85 0.000982
0.29 0.047104 1.16 0.001010
The up-regulation is expressed as the log2 ratio as compared to HUVECs. For MAPK1 we observed down-regulation. All values (except one written 
in italic) are statistically significant. Double values refer to transcription variants of the gene. n.r. = not regulated.
Table 1: VEGFR3 quantification in cell lysates by ELISA
Cell type Total protein [mg/ml] Concentration [ng/ml] Concentration [ng/mg protein]
HUVEC 0.67 1.77 2,65 +/- 0.06
HAEC 1.09 1.51 1.38 +/- 0.03
UtMVECmyo 1.03 1.64 1.60 +/- 0.01
HDMEC 0.36 2.78 7.73 +/- 0.61
HDMEC Lyve1+ 0.53 10.25 19.34 +/- 0.75
LEC A 0.60 17.71 29.51 +/- 2.25
LEC B 0.42 17.15 40.84 +/- 1.66
Protein levels of VEGFR3 in various endothelial cell types measured by ELISA. Cell lysates were prepared from confluent cells and after dilution 
lysate samples were measured in triplicates. Indicated is the mean of VEGFR3 protein concentration in ng per mg of total protein (+/- SD).BMC Cancer 2007, 7:105 http://www.biomedcentral.com/1471-2407/7/105
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